Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-lung 1 histology subgroups
Yükleniyor...
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
ELSEVIER
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroups
Açıklama
Anahtar Kelimeler
Kaynak
ANNALS OF ONCOLOGY
WoS Q Değeri
Q1
Scopus Q Değeri
Cilt
33
Sayı
7
Künye
Sezer, A., Kilickap, S., Gumus, M., Bondarenko, I., Ozguroglu, M., Gogishvili, M., ... & Quek, R. (2022). 1183P Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroups. Annals of Oncology, 33, S1089.
